Ingrid Delaet, serving as the Chief Regulatory Officer for Neurocrine Biosciences Inc. (NASDAQ:NBIX), completed a series of equity transactions resulting in the liquidation of common stock valued at approximately $2.6 million. The sales were executed between July 7 and July 9, 2026, and were structured to follow the acquisition of an identical number of shares through the exercise of stock options. This methodical approach to equity management aligns with standard practices for executive compensation and liquidity planning within the biopharmaceutical industry. The transactions occurred while the company's shares were trading in close proximity to their 52-week high of $181, with the stock price recorded at $180.59. Neurocrine has demonstrated significant momentum, delivering a 33% return over the past six months and posting a 27% gain year-to-date, reflecting strong market confidence in its strategic direction.
During the three-day window, Ms. Delaet disposed of a total of 14,571 shares of Neurocrine Biosciences common stock. The initial tranche on July 7 involved the sale of 3,401 shares, executed at prices ranging from $178.52 to $178.75 per share. The following day, July 8, saw the sale of an additional 2,737 shares, with transaction prices falling between $178.52 and $178.59. The largest portion of the liquidation took place on July 9, where 8,433 shares were sold at prices ranging from $178.52 to $179.19. The aggregate proceeds from these dispositions totaled approximately $2,603,111. All sales were facilitated by a broker in accordance with instructions outlined in a Rule 10b5-1 trading plan, which Ms. Delaet adopted on February 27, 2026. This pre-arranged framework ensures compliance with insider trading regulations while providing a predictable mechanism for equity liquidation.
Simultaneously with the sales, Ms. Delaet acquired 14,571 shares of common stock through the exercise of non-qualified stock options. The acquisition was made at an exercise price of $103.52 per share, resulting in a total cost of approximately $1,508,389. These options were originally granted on February 13, 2023, and are scheduled to vest in 48 equal monthly installments. Following these concurrent transactions, Ms. Delaet's direct holdings in Neurocrine Biosciences common stock stand at 16,225 shares. Market analysis suggests that Neurocrine appears undervalued at current levels based on its Fair Value assessment, placing it among stocks on the Most Undervalued list. Investors seeking deeper insights can access a comprehensive Pro Research Report on NBIX, one of 1,400+ available reports that transform complex Wall Street data into clear, actionable intelligence.
In other recent developments, Neurocrine Biosciences Inc. has initiated a Phase 2 clinical study to evaluate crinecerfont in infants with classic congenital adrenal hyperplasia. The study will enroll 20 participants and aims to assess the safety and tolerability of the drug over a 24-week treatment period. In addition to this development, Neurocrine presented long-term data on VYKAT XR at ENDO 2026, focusing on its effects on hyperphagia in Prader-Willi syndrome patients. The study involved 77 participants and explored the potential benefits of restarting VYKAT XR after a withdrawal period.
Neurocrine also shared findings from a retrospective case series on the use of CRENESSITY in patients with a rare subtype of congenital adrenal hyperplasia. This study included 15 patients and highlighted a condition not previously studied in clinical trials. Moreover, two-year data from the Phase 3 CAHtalyst Pediatric study indicated that treatment with Crenessity led to slowed bone age progression in pediatric patients with classic congenital adrenal hyperplasia. In terms of analyst perspectives, Stifel reiterated a Buy rating for Neurocrine Biosciences, expressing confidence in the potential of Vykat to achieve over $1 billion in peak sales. However, Stifel noted that near-term growth might face challenges before reaching a steady state. These developments reflect the company's ongoing efforts in research and its promising pipeline of treatments.